---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-196582"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2022-07-19T23:59:59+00:00"
generated_at: "2026-06-24T12:26:47.808883+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amneal subsidiary settles Opana ER antitrust litigation for $265M; records Q2 charge

## Summary
- Impax subsidiary agrees to pay $265M plus interest to settle Opana ER antitrust class actions.
- Settlement covers direct purchaser, indirect purchaser, and individual claims in MDL.
- Company to record pre-tax charge of approx. $265M in Q2 2022.
- Payments to be made between 2022 and Jan 2024; funded by cash on hand, cash flow, and revolver.
- Settlement is not an admission of liability; subject to court approval.

## SEC filing metadata
- accession: 0001193125-22-196582
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2022-07-19T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000119312522196582/0001193125-22-196582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000119312522196582/d320133d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-196582
- JSON: https://secwatch.observer/filing/0001193125-22-196582.json
- Plain text: https://secwatch.observer/filing/0001193125-22-196582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.